Extract of Ginkgo biloba ameliorates streptozotocin- induced type 1 diabetes mellitus and high-fat diet- induced type 2 diabetes mellitus in mice

International Journal of Medical Sciences

Volumn 12, Issue 12, 2015, Pages 987-994

  Rhee, Ki Jong ^a   Lee, Chang Gun ^a   Kim, Sung Woo ^b   Gim, Dong Hyeon ^c   Kim, Hyun Cheol ^c   Jung, Bae Dong ^b,c  

^a Yonsei University Wonju   (South Korea)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Kangwon National University   (South Korea)

Author keywords

Diabetes mellitus; Extract of gingko biloba; High fat diet; Streptozotocin

Indexed keywords

GINKGO BILOBA EXTRACT; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; AUTACOID; GINKGO BILOBA EXTRACT 761; GLUCOSE BLOOD LEVEL; PLANT EXTRACT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIVER LEVEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GINKGO BILOBA; LIPID DIET; LIVER; MALE; METABOLISM; PHYTOTHERAPY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GINKGO BILOBA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INTERLEUKIN-1BETA; LIPOPROTEIN LIPASE; LIVER; MALE; MICE; MICE, INBRED C57BL; PHYTOTHERAPY; PLANT EXTRACTS; PPAR ALPHA; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84949485334     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.13339     Document Type: Article

References (39)

1. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015; 6: 850-67.
2. Gaba R, Gambhire D, Uy N, Gonzalez EV, Iyer D, Hampe CS, et al. Factors associated with early relapse to insulin dependence in unprovoked A-β+ ketosis- prone diabetes. J Diabetes Complications. 2015.
3. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982; 54: 254-60.
4. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983; 72: 1150-62.
5. Dwarakanathan A. Diabetes update. J Insur Med. 2006; 38: 20-30.
6. Walker CG, Zariwala MG, Holness MJ, Sugden MC. Diet, obesity and diabetes: a current update. Clin Sci (Lond). 2007; 112: 93-111.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31: 173-5.
8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005-12.
9. van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J chromatogr A. 2009; 1216: 2002-32.
10. Mohanta TK, Tamboli Y, Zubaidha PK. Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod Res. 2014; 28: 746-52.
11. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr pharm Des. 2004; 10: 261-4.
12. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci. 2008; 73: R14-9.
13. Oyama Y, Chikahisa L, Ueha T, Kanemaru K, Noda K. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain res. 1996; 712: 349-52.
14. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug targets. 2000; 1: 25-58.
15. Silberstein RB, Pipingas A, Song J, Camfield DA, Nathan PJ, Stough C. Examining brain-cognition effects of ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task. Evid Based Complement Alternative Med. 2011; 2011: 164139.
16. Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol. 1994; 234: 462-75.
17. Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001; 15: 449-51.
18. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm. 2006; 2006: 92642.
19. Zhang Q, Wang GJ, A JY, Wu D, Zhu LL, Ma B, et al. Application of GC/MS-based metabonomic profiling in studying the lipid-regulating effects of Ginkgo biloba extract on diet-induced hyperlipidemia in rats. Acta Pharmacol Sin. 2009; 30: 1674-87.
20. Drieu K, Vranckx R, Benassayad C, Haourigi M, Hassid J, Yoa RG, et al. Effect of the extract of Ginkgo biloba (EGb 761) on the circulating and cellular profiles of polyunsaturated fatty acids: correlation with the anti-oxidant properties of the extract. Prostaglandins Leukot Essent Fatty Acids. 2000; 63: 293-300.
21. Saini AS, Taliyan R, Sharma PL. Protective effect and mechanism of Ginkgo biloba extract-EGb 761 on STZ-induced diabetic cardiomyopathy in rats. Pharmacogn Mag. 2014; 10: 172-8.
22. Park JB, Lee JS, Cho BP, Rhee K-J, Baik SK, Kim J, Kang SJ, Park D-J, Oh J-E, Shin HC, Kim YM, Kim HS, Bae KS, Eom YW. Adipose tissue-derived mesenchymal stem cells cultured at high cell density express brain-derived neurotrophic factor and exert neuroprotective effects in a 6-hydroxydopamine rat model of Parkinson’s disease. Gen Genom. 2015; 37: 213-21.
23. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun. 2010; 393: 118-22.
24. Samarghandian S, Azimi-Nezhad M, Samini F. Ameliorative effect of saffron aqueous extract on hyperglycemia, hyperlipidemia, and oxidative stress on diabetic encephalopathy in streptozotocin induced experimental diabetes mellitus. Biomed Res Int. 2014; 2014: 920857.
25. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator- activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998; 273: 29577-85.
26. Li YG, Ji DF, Zhong S, Lin TB, Lv ZQ. Hypoglycemic effect of deoxynojirimycin- polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism. Chem Biol Interact. 2015; 225: 70-9.
27. Wang X, Huang M, Wang Y. The effect of insulin, TNFα and DHA on the proliferation, differentiation and lipolysis of preadipocytes isolated from large yellow croaker (Pseudosciaena Crocea R.). PLoS One. 2012; 7: e48069.
28. Yao P, Song F, Li K, Zhou S, Liu S, Sun X, et al. Ginkgo biloba extract prevents ethanol induced dyslipidemia. Am J Chin Med. 2007; 35: 643-52.
29. Koulmanda M, Qipo A, Auchincloss H, Jr., Smith RN. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol. 2003; 134: 210-6.
30. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes. 2005; 54: 1423-8.
31. Chen CC, Chiang AN, Liu HN, Chang YT. EGb-761 prevents ultraviolet B-induced photoaging via inactivation of mitogen-activated protein kinases and proinflammatory cytokine expression. J Dermatol Sci. 2014; 75: 55-62.
32. Yin D, Tao J, Lee DD, Shen J, Hara M, Lopez J, et al. Recovery of islet β-cell function in streptozotocin- induced diabetic mice: an indirect role for the spleen. Diabetes. 2006; 55: 3256-63.
33. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. β cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest. 2002; 109: 1153-63.
34. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007; 117: 2621-37.
35. Grundy SM, Mok HY, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest. 1979; 63: 1274-83.
36. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999; 84: 28J-32J.
37. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep. 2002; 4: 494-500.
38. Camps L, Reina M, Llobera M, Bengtsson-Olivecrona G, Olivecrona T, Vilaro S. Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution. J Lipid Res. 1991; 32: 1877-88.
39. Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ, et al. Hormone- sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab. 2005; 289: E30-9.